<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03933943</url>
  </required_header>
  <id_info>
    <org_study_id>17180</org_study_id>
    <secondary_id>I9S-MC-BTAB</secondary_id>
    <nct_id>NCT03933943</nct_id>
  </id_info>
  <brief_title>A Study of LY3361237 in Participants With Systemic Lupus Erythematosus</brief_title>
  <official_title>A Phase 1, Randomized, Placebo-Controlled, Multiple- Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3361237 in Patients With Systemic Lupus Erythematosus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to learn more about the safety of LY3361237 and any side&#xD;
      effects that might be associated with it when given to participants with systemic lupus&#xD;
      erythematosis (SLE). LY3361237 will be administered by injections just under the skin. The&#xD;
      study will last up to 26 weeks and may include up to 17 visits to the study center.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 21, 2019</start_date>
  <completion_date type="Actual">February 15, 2021</completion_date>
  <primary_completion_date type="Actual">February 15, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug</measure>
    <time_frame>Baseline through Day 155</time_frame>
    <description>A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3361237</measure>
    <time_frame>Day 1 predose through Day 155</time_frame>
    <description>PK: Cmax of LY3361237</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Area Under the Concentration Versus Time Curve (AUC) Over the Dosing Interval of LY3361237</measure>
    <time_frame>Day 1 predose through Day 155</time_frame>
    <description>PK: AUC Over the Dosing Interval of LY3361237</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Lupus Erythematosus, Systemic</condition>
  <arm_group>
    <arm_group_label>LY3361237</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3361237 administered subcutaneously (SC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered SC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3361237</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>LY3361237</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants must have received a diagnosis of SLE at least 24 weeks before screening&#xD;
             (at least 4 of 11 criteria in 1997 revised American College of Rheumatology [ACR]&#xD;
             classification)&#xD;
&#xD;
          -  If a participant is taking oral prednisone (or prednisone equivalent) for SLE, the&#xD;
             dose must be ≤20 milligrams per day (mg/day) for at least 8 weeks prior to screening,&#xD;
             and must have been stable for at least the last 2 weeks&#xD;
&#xD;
          -  If a participant is taking any of the following medications for SLE, the medication&#xD;
             must have been used for at least 12 weeks and stable for at least the last 8 weeks:&#xD;
&#xD;
               -  Azathioprine ≤200 mg/day&#xD;
&#xD;
               -  Antimalarial (e.g., chloroquine, hydroxychloroquine, quinacrine)&#xD;
&#xD;
               -  Mycophenolate mofetil ≤2 g/day or mycophenolic acid ≤1.44 grams per day (g/day)&#xD;
&#xD;
               -  Oral, SC, or intramuscular methotrexate ≤15 milligrams per week (mg/week)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants must not have a history of, or current, inflammatory joint or skin&#xD;
             disease other than SLE&#xD;
&#xD;
          -  Participants must not have a current active bacterial, viral, or fungal infection&#xD;
&#xD;
          -  Participants must not have evidence of significant liver or kidney dysfunction&#xD;
&#xD;
          -  Participants must not have received cytotoxic medications (e.g., cyclophosphamide)&#xD;
             within the last 3 months.&#xD;
&#xD;
          -  Participants must not have received any intra-articular, intramuscular, or intravenous&#xD;
             glucocorticoids within the last 3 months&#xD;
&#xD;
          -  Participants must not have received blood products (e.g., blood transfusion,&#xD;
             platelets, etc.) within the last 12 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pinnacle Research Group</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of West Florida</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of West Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Georgia Rheumatology, PC</name>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <zip>30046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DJL Clinical Research, PLLC</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paramount Medical Research</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altoona Center For Clinical Research</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Tennessee Research Institute</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accurate Clinical Management LLC - Katy</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77084</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trials.lillytrialguide.com/en-US/trial/eiRWT5wAOkRpZOHEo4Ira</url>
    <description>A Study of LY3361237 in Participants With Systemic Lupus Erythematosus</description>
  </link>
  <verification_date>March 1, 2021</verification_date>
  <study_first_submitted>April 30, 2019</study_first_submitted>
  <study_first_submitted_qc>April 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2019</study_first_posted>
  <last_update_submitted>March 3, 2021</last_update_submitted>
  <last_update_submitted_qc>March 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

